Channelpedia

PubMed 20581741


Referenced in Channelpedia wiki pages of: none

Automatically associated channels: Cav3.1 , Kir6.2 , Kv1.2



Title: Patterns of gene expression in the ductus arteriosus are related to environmental and genetic risk factors for persistent ductus patency.

Authors: Nahid Waleh, Ryan Hodnick, Nami Jhaveri, Suzanne McConaghy, John Dagle, Steven Seidner, Donald McCurnin, Jeffrey C Murray, Robin Ohls, Ronald I Clyman

Journal, date & volume: Pediatr. Res., 2010 Oct , 68, 292-7

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/20581741


Abstract
Three independent risk factors (immature gestation, absence of antenatal glucocorticoid exposure, and presence of the rs2817399(A) allele of the gene TFAP2B) are associated with patent ductus arteriosus (PDAs) that fail to close during prostaglandin inhibition. We hypothesized that these three factors may affect a common set of genes that increase the risk of persistent PDA after birth. We studied baboon ductus from term, preterm, and glucocorticoid-treated preterm fetuses and found that both immature gestation and absence of antenatal glucocorticoid exposure decreased RNA expression of calcium- and potassium-channel genes involved in oxygen-induced constriction, and phosphodiesterase genes (that modulate cAMP/cGMP signaling). Ductus obtained from second trimester human pregnancies were genotyped for TFAP2B polymorphisms. When present, the rs2817399(A) allele also was associated with decreased expression of calcium- and potassium-channel genes. In contrast, alleles of two other TFAP2B polymorphisms, rs2817419(G) and rs2635727(T), which are not related to the incidence of PDA after birth, had no effect on RNA expression. In conclusion, three calcium- and potassium-channel genes (CACNA1G/ alpha1G, CACNB 2/CaL-beta2, and KCNA2/ Kv1.2) were similarly affected by each of the PDA risk factors. We speculate that these channels may play a significant role in closing the preterm ductus during prostaglandin inhibition and may be potential targets for future pharmacologic manipulations.